The management of type II diabetes using Thiazolidinediones (TZDs), which are PPARG agonists, is controversial because of their known adverse effects, including increased body fat, bone loss, edema, liver dysfunction, and potential cardiovascular risks [9,10,11]. The gene discussed is PPARG; the disease is type 2 diabetes mellitus.